Thrivent Financial for Lutherans
NTLA icon

Thrivent Financial for Lutherans’s Intellia Therapeutics NTLA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$281K Buy
16,625
+5,104
+44% +$71.4K ﹤0.01% 2471
2026
Q1 		$148K Buy
+11,521
New +$147K ﹤0.01% 2498
2025
Q3 		– Sell
-64,211
Closed -$603K – 2535
2025
Q2 		$603K Hold
64,211
– – ﹤0.01% 2053
2025
Q1 		$456K Hold
64,211
– – ﹤0.01% 2108
2024
Q4 		$749K Buy
64,211
+33,878
+112% +$529K ﹤0.01% 2053
2024
Q3 		$623K Hold
30,333
– – ﹤0.01% 2157
2024
Q2 		$679K Buy
+30,333
New +$722K ﹤0.01% 2076

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Thrivent Financial for Lutherans's NTLA Position: Q2 2026 in Review

Thrivent Financial for Lutherans increased its Intellia Therapeutics (NTLA) stake by 44% in Q2 2026, buying an estimated $71.4K and bringing the position to 16,625 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #2471.

Thrivent Financial for Lutherans first reported a position in NTLA in Q2 2024 and has held it in 7 quarters since. The position peaked at $749K in Q4 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Thrivent Financial for Lutherans held 16,625 shares of Intellia Therapeutics worth $281K as of Q2 2026.
  • Thrivent Financial for Lutherans bought 5,104 Intellia Therapeutics shares in Q2 2026, an estimated $71.4K.
  • Intellia Therapeutics made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #2471 holding.
  • Thrivent Financial for Lutherans first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Thrivent Financial for Lutherans's Intellia Therapeutics position peaked at $749K in Q4 2024.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.